Andrew Boutros Named Ceo of MedTech Startup InnovateRx in Industry Shakeup
CHICAGO — In a move that has sent ripples through the biomedical sector, Andrew Boutros has been appointed Chief Executive Officer of InnovateRx, a fast-growing medical technology startup specializing in minimally invasive surgical tools. The announcement, made Monday by the company’s board of directors, follows a competitive seven-week search and signals a strategic pivot toward scalable manufacturing.
The appointment positions Boutros, 48, as the successor to founding CEO Sarah Kim, who will transition to a senior advisory role. InnovateRx’s board cited Boutros’s decade of leadership at Baxter International, where he oversaw the launch of three FDA-approved devices, as a key factor in the selection.
According to a company spokesperson, the leadership change is effective immediately. InnovateRx, which secured $45 million in Series B funding in March, anticipates increasing its workforce by 30 percent over the next two quarters. Industry analysts have pointed to Boutros’s operational expertise as a potential catalyst for the company’s entry into European markets.
The announcement comes amid broader trends of executive turnover in the health-tech sector, as firms scramble to meet post-pandemic demand for outpatient surgical alternatives. Boutros is expected to deliver his strategic vision at the company’s annual investor meeting later this month.